Development of the Extended Infusion Set and Its Mechanism of Action

Citations of this article
Mendeley users who have this article in their library.

This article is free to access.


Continuous subcutaneous insulin infusion (CSII, or insulin pump) and continuous glucose monitoring (CGM) sensors have been increasingly used and associated with improved glycemic control by people with type 1 diabetes and insulin-requiring type 2 diabetes. Commonly used infusion sets in most CSII systems are limited to a wear time of 3 days. In contradistinction, CGM sensors are currently approved for seven and more days of wear. With the motivation to provide a 7-day infusion set that matches the CGM wear time and to improve patient experience, the recently CE-marked and FDA 510k–cleared Medtronic extended infusion set (EIS) was designed. The EIS offers enhanced new features that include use for up to 7 days, improved convenience, comfort, and better quality of life for insulin pump users.




Zhang, G., Cohen, O., & Chattaraj, S. (2022). Development of the Extended Infusion Set and Its Mechanism of Action. Journal of Diabetes Science and Technology.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free